Physician profile
Vanessa L Wall
NPI 1417260019
$3,958.35
in general payments reported to CMS, 2019-2025
24 companies · $770 in 2025
The $770 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $128 · 2021: $507 · 2022: $539 · 2023: $729 · 2024: $629 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,022 · Entertainment: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,022.19 |
| Entertainment | $105.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $815.26 | 2022-2025 | Durysta, Xen Glaucoma Treatment System, Ozurdex |
| Sight Sciences, INC. | $556.94 | 2019-2025 | Omni Surgical System |
| Biotissue Holdings INC. | $520.98 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $373.84 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $297.20 | 2022-2025 | Acthar |
| Bausch & Lomb Americas INC. | $281.93 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $261.71 | 2021-2022 | |
| Optos, INC. | $153.08 | 2020-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Alcon Vision LLC | $126.55 | 2019-2021 | |
| Shire North American Group INC | $109.58 | 2019 | |
| Oyster Point Pharma, INC. | $109.29 | 2022-2024 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $80.90 | 2019-2023 | |
| Rayner Intraocular Lenses Limited | $55.72 | 2022-2025 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Sun Pharmaceutical Industries INC. | $40.88 | 2022-2024 | |
| Aerie Pharmaceuticals, INC. | $27.05 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $23.80 | 2019 | |
| Harrow Eye, LLC | $21.64 | 2024 | Vevye |
| Glaukos Corporation | $15.67 | 2020 | |
| Eyepoint US, INC. | $15.42 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.10 | 2019 | |
| Omeros Corporation | $14.56 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $14.46 | 2019 | |
| Eyevance Pharmaceuticals LLC | $13.81 | 2019 | |
| Vyera Pharmaceuticals, LLC | $12.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Wall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.